Literature DB >> 9179114

Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision.

J Hida1, M Yasutomi, T Maruyama, K Fujimoto, T Uchida, K Okuno.   

Abstract

BACKGROUND: Total mesorectal excision effectively reduces the local recurrence rate of carcinoma of the rectum. This study was undertaken to clarify the rationale for total mesorectal excision. STUDY
DESIGN: We retrospectively reviewed the records of 198 patients who underwent resection of a carcinoma of the rectum. The presence of nodal metastases in the mesorectum distal to the primary tumor was examined by the clearing method.
RESULTS: The metastatic rate in the distal mesorectum was 20.2 percent. The metastatic rates according to the extent and site of the tumor were as follows: pT1, 0 percent; pT2, 0 percent; pT3, 21.9 percent; pT4, 50 percent; rectosigmoid, 10 percent; upper rectum, 26.3 percent; and lower rectum, 19.2 percent. The longest distal spread from the primary tumor to the metastatic node was 2 cm in carcinoma of the rectosigmoid, 4 cm in carcinoma of the upper rectum, and 3 cm in carcinoma of the lower rectum.
CONCLUSIONS: Total mesorectal excision is required for patients with T3 and T4 tumors in the lower rectum, and excision of all mesorectal tissue down to at least 5 cm below the tumor is required for patients with T3 and T4 tumors in the upper rectum.

Entities:  

Mesh:

Year:  1997        PMID: 9179114

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  28 in total

Review 1.  Total mesorectal excision: technical aspects.

Authors:  P Terry Phang
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

Review 2.  High ligation of the inferior mesenteric artery in rectal cancer surgery.

Authors:  Jin-Ichi Hida; Kiyotaka Okuno
Journal:  Surg Today       Date:  2012-10-07       Impact factor: 2.549

3.  A Prospective Study of Distal Microscopic Spread in Rectal Cancer After Neoadjuvant Chemoradiation in Pinned and Unpinned Specimen.

Authors:  Aravind S Kapali; K Chandramohan; A V Jayasudha
Journal:  Indian J Surg Oncol       Date:  2017-03-18

4.  Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum.

Authors:  Cun Wang; Zongguang Zhou; Zhao Wang; Yangchun Zheng; Gaoping Zhao; Yongyang Yu; Zhong Cheng; Daiyun Chen; Weiping Liu
Journal:  Langenbecks Arch Surg       Date:  2005-06-14       Impact factor: 3.445

5.  The clinical significance of distal spread differs according to the primary tumor location in rectal cancer.

Authors:  Kaoru Abe; Yoshifumi Shimada; Hidehito Oyanagi; Ryoma Yagi; Masato Nakano; Hitoshi Kameyama; Hitoshi Nogami; Satoshi Maruyama; Yasumasa Takii; Toshifumi Wakai
Journal:  Surg Today       Date:  2019-09-30       Impact factor: 2.549

Review 6.  Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options.

Authors:  Daniel C Damin; Anderson R Lazzaron
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 7.  Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer.

Authors:  Jin-ichi Hida; Kiyotaka Okuno; Tadao Tokoro
Journal:  Surg Today       Date:  2013-12-22       Impact factor: 2.549

8.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

9.  The pathological assessment of mesorectal excision: implications for further treatment and quality management.

Authors:  P Hermanek; P Hermanek; W Hohenberger; M Klimpfinger; F Köckerling; T Papadopoulos
Journal:  Int J Colorectal Dis       Date:  2003-02-14       Impact factor: 2.571

10.  In vivo lymph node mapping and pattern of metastasis spread in locally advanced mid/low rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  E Farinella; L Viganò; M C Fava; M Mineccia; F Bertolino; L Capussotti
Journal:  Int J Colorectal Dis       Date:  2013-07-23       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.